Latest News & Features
Big Pharma
Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’. 29 June 2023
Big Pharma
Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP. 29 June 2023
Medtech
More clarity is needed on the application of Alice and Mayo to patent eligibility—particularly for firms developing innovative medical diagnostic techniques, say Kara Specht and Yinan Liu of Finnegan. 27 June 2023
Big Pharma
UPC Administrative Committee 'voted unanimously' to approve Milan says Italian politician | Court will hear patent cases related to “pharmaceutical, phytosanitary, agri-food and fashion” | Chemistry and metallurgy moving to Munich, excluding SEPs. 27 June 2023
Europe
Dame Sue Carr takes over from Lord Burnett of Maldon, assuming responsibilities in October. 22 June 2023
Americas
Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws. 22 June 2023
Americas
Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year. 22 June 2023
Big Pharma
Pharma giant claims infringement of two patents |
Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details. 20 June 2023
Americas
Both drug treatments inhibit a protein called Bruton’s tyrosine kinase that can trigger cancer | Lawsuit comes in wake of patent grant for disputed drug | New study caused headaches for AbbVie’s subsidiary. 20 June 2023
Americas
The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026. 15 June 2023